Latus Bio
latusbio.com
Neurology & CNS Therapeutics
Biotechnology
Cell & Gene Therapy
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
DCVCVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Biotech raises $42 million to run Huntington's disease trial
Biotech startup, Latus Bio, raised $42 million as it prepares to seek FDA permission to start a clinical trial to test its gene therapy for Huntington's disease.
Read more
Report
Optimized AAV capsids for basal ganglia diseases show robust potency and distribution
Huntington's disease and other disorders of the basal ganglia create challenges for biomolecule-based medicines given the poor accessibility of these deep brain structures following intracerebral or intravascular delivery. Here, we found that low dose, lo
Read more
Report
BioSpace's NextGen Class of 2025 Leans Into Biopharma's Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma's most competitive therapeutic spaces-and attracting dollars from Big Pharma.
Read more
Report
How capsid screening could unleash CNS genetic therapies at scale
With its novel adeno-associated virus discovery platform, Latus Bio is addressing problems associated with high-dose gene therapy for central nervous system diseases, aiming to usher in a new era of safer, more effective, and lower cost treatments.
Read more
Report
Report
Read full news
Latus Bio Announces Four Abstracts Selected for Presentation at the European Society of Gene and Cell Therapy 33rd Annual Congress
Read more
Report
Read full news
Latus Bio Announces New Data Presentation at American Society of Nephrology (ASN) Kidney Week 2026
Read more
Report
Read full news
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
Read more
Report
Report
Read full news
Latus Bio Announces 97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Read more
Report
Show more news